Stock VPH VALEO PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Valeo Pharma Inc.

Valeo Pharma Inc. Stock price Canadian Securities Exchange

Equities

VPH

CA91915B1085

Pharmaceuticals

Delayed Canadian Securities Exchange
Other stock markets
 03:57:37 2022-03-28 pm EDT 		Intraday chart for Valeo Pharma Inc. 5-day change 1st Jan Change
0.6600 CAD -.--% +1.54% -10.81%
Nov. 20 Valeo Pharma Announces Organizational Changes and Cost Reduction Initiatives; Shares Jumped Near 30% Friday MT
Nov. 20 Valeo Pharma Inc. Announces Chief Financial Officer Changes CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site

Financials

Sales 2023 * 56.93 M 41.86 M Sales 2024 * 74.35 M 54.68 M Capitalization 15.29 M 11.24 M
Net income 2023 * -24.00 M -17.65 M Net income 2024 * -14.00 M -10.30 M EV / Sales 2023 *
0,27x
Net cash position 2023 * - 0 Net Debt 2024 * 58 42 EV / Sales 2024 *
0,21x
P/E ratio 2023 *
-0,54x
P/E ratio 2024 *
-1,11x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 51.93%
More Fundamentals * Assessed data

Chart Valeo Pharma Inc.

Dynamic Chart

Latest news about Valeo Pharma Inc.

Valeo Pharma Announces Organizational Changes and Cost Reduction Initiatives; Shares Jumped Near 30% Friday MT
Valeo Pharma Inc. Announces Chief Financial Officer Changes CI
Valeo Pharma Brief: Expected to generate annual savings exceeding $2 million MT
Valeo Pharma Brief: Announcing Organizational Changes and Cost Reduction Initiatives MT
Valeo Pharma Inc. Announces Appointment of Mr. Richard Lajoie to Board of Directors CI
Valeo Pharma Entered Into $5 Million Credit Facilty Agreement With Accord Financial Inc. MT
Valeo Pharma Enters into $5 Million Credit Facility Agreement with Accord Financial Inc CI
Valeo Pharma's Fiscal Q3 Loss Widens, Revenue Grows; Up 3.5% MT
Transcript : Valeo Pharma Inc., Q3 2023 Earnings Call, Sep 14, 2023 CI
Valeo Pharma's Fiscal Q3 Loss Widens, Revenue Grows MT
Valeo Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023 CI
Valeo Pharma Closes $4.5 Million Financing; Gained 14.5% on Thursday MT
Valeo Pharma Inc. announced that it has received CAD 4.499999 million in funding from Investissement Québec CI
Valeo Pharma Providing Update On Ophthalmology Business Unit MT
Valeo Pharma Brief: Novartis agrees to sell global rights to XIIDRA and several other ophthalmology products to Baucsh + Lomb; SIMBRINZA not included in the divestiture MT
More news

Press releases Valeo Pharma Inc.

Valeo Pharma announces new chief financial officer along with $2 million in cost reductions AQ
VALEO PHARMA ANNOUNCES ORGANIZATIONAL CHANGES AND COST REDUCTION INITIATIVES AQ
VALEO PHARMA ANNOUNCES APPOINTMENT OF MR. RICHARD LAJOIE TO BOARD OF DIRECTORS AQ
Valeo Pharma CEO credits Enerzair for strong position on Canada̢۪s top-growing companies list AQ
VALEO PHARMA MAKES THE LIST OF THE GLOBE AND MAIL'S FIFTH-ANNUAL RANKING OF CANADA'S TOP GROWING COMPANIES AQ
More press releases

Managers and Directors - Valeo Pharma Inc.

Managers TitleAgeSince
Steven Saviuk FOU
 Founder 64 2003
Luc Mainville DFI
 Director of Finance/CFO 59 2018
Nelly Komari CTO
 Chief Tech/Sci/R&D Officer - 2021
Members of the board TitleAgeSince
Richard MacKay CHM
 Chairman 88 2018
Steven Saviuk FOU
 Founder 64 2003
Michel Claude Trudeau BRD
 Director/Board Member - 2019
More insiders

Company Profile

Valeo Pharma Inc. is a Canada-based specialty pharmaceutical company. The Company acquires or in-licenses brand and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology, specialty products, hospital generic division. Its respiratory/allergy products include Enerzair, Breezhaler, Atectura, Breezhaler and Allerject. Its ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis, Hesperco and Ametop Gel 4%. Its hospital generic division includes Benztropine, Ethacrynate Sodium and Amikacin. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.
Sector
Pharmaceuticals
Calendar
2024-02-27 - Q4 2023 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.1550CAD
Average target price
0.8250CAD
Spread / Average Target
+432.26%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi. (M$)
VALEO PHARMA INC. Stock Valeo Pharma Inc.
-10.81% 11 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+61.78% 532 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+46.99% 452 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-13.89% 365 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-8.85% 254 B $
ABBVIE INC. Stock AbbVie Inc.
-14.30% 244 B $
ROCHE HOLDING AG Stock Roche Holding AG
-18.62% 216 B $
NOVARTIS AG Stock Novartis AG
+1.50% 200 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-10.57% 195 B $
PFIZER, INC. Stock Pfizer, Inc.
-41.30% 168 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Valeo Pharma Inc.
  4. Stock Valeo Pharma Inc. - Canadian Securities Exchange
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer